Description
Indications
ILUDX , • (MCL) • CLL / SLL • 17p (CLL)/ (SLL) • (WM) • (MZL) ILUDX
Mécanisme d’action
12.1 Mecanisme d action (BTK) BTK , BTK BTK B (BCR) BTK B , B , B ,
Pharmacologie
12 12.1 Mecanisme d action (BTK) BTK , BTK BTK B (BCR) BTK B , B , B ,
Posologie
2 / (CLL/SLL) (WM) , 420 mg (2.1) (cGVHD) ◦ 12 , 420 mg (2.1) ◦ 1 12 , 240 mg/m² 420 mg (2.1)
Interactions médicamenteuses
7 CYP3A IMBRUVICA 2.3,7.1 CYP3A CYP3A 7.2 7.1 CYP3A IMBRUVICA CYP3A [ 12.3 ] CYP3A , IMBRUVICA [ Posologie 2.3 ]
Effets indésirables
ILUDX , • ILUDX , , , , • • • • • , • • • • • • ILUDX , ILUDX , • ILUDX , • ILUDX , , , • ILUDX • ILUDX , • (TLS) TLS TLS , TLS ILUDX • • • • • • • ILUDX ILUDX , , ILUDX ,
